|
|
Article: Surge in Strategic Alliances and Licensing Deals to Boost Productivity of Pharmaceutical Companies.
- Article from:
- PR Newswire
- Article date:
- May 10, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, May 10 /PRNewswire/ -- A steep decline in innovation levels, combined with the threat from generics and drug recalls is causing concern to several pharmaceutical companies. As a result, pharmaceutical companies across the world are collaborating with biotech companies, thus relying on external resources to boost their innovation and productivity levels.
"Having unsuccessfully implemented merger and acquisition (M&A) strategies to boost their falling productivity levels, pharmaceutical companies are now developing strategic alliances and licensing deals to improve weakening drug pipelines and achieve sustainable revenue growth," notes Frost &Sullivan ...